Your Trusted IPO & Stock Intelligence Partner
Avience Biomedicals IPO Review: Analyzing Noida's Growing Diagnostic Player
An in-depth evaluation of Avience Biomedicals Limited’s market debut, financial fundamentals, capacity expansion roadmap, and investment potential.
IPO Lifecyle Timeline & Status Tracker
Corporate Overview: What Does Avience Biomedicals Do?
Established in June 2024, Avience Biomedicals Limited is an ISO-certified diagnostic developer specializing in manufacturing, exporting, and supplying molecular diagnostic solutions. Positioned dynamically in the biotechnology, genomics, and In-Vitro Diagnostics (IVD) segment, the enterprise has quickly extended its original catalog from IVD rapid diagnostic kits to a versatile catalog of biochemistry analyzers, medical devices, and serological assets.
Serving exclusively B2B (Business-to-Business) and B2G (Business-to-Government) market networks, the firm caters to pathology clinics, research hubs, healthcare institutions, and microbiological facilities both nationally and globally. Its modern production center is located in Noida, Uttar Pradesh.
Key Diagnostic Verticals & Offerings:
- Rapid Testing Infrastructure: Featuring the AVISURE Dengue Combo system, Malaria Rapid Test configurations, and Syphilis detection kits.
- Clinical Biochemistry: Including the BS-240 Automated Biochemistry Analyzer along with standard reagents.
- Advanced Molecular Assays: High-precision COVID-19 RTqPCR assay formulations.
- Hematological Assays: High-throughput models such as the BC-20s 3-Part Analyzer.
- Critical Care Devices: Oxygen concentrators (Oxy-5/Oxy-10) and viral transport medium (VTM) units.
- Distribution Division: Direct trading operations of high-performance third-party diagnostic equipment.
IPO Specifications & Offer Structure
| Key Market Parameters | Details & Figures |
|---|---|
| Issue Date Window | June 18, 2026 to June 22, 2026 |
| Pricing Bracket | ₹196 to ₹208 per equity share |
| Final Offer Valuation | ₹208 per equity share |
| Aggregate Issue Capitalization | ₹30.24 Crore |
| Total Shares Offered | 14,53,800 Equity Shares |
| Issue Composition | 100% Fresh Capital Injection |
| Face Value | ₹10 per share |
| Exchange Listing Destination | NSE SME Platform |
| Market Maker Assignment | Asnani Stock Broker Pvt. Ltd. (82,200 shares allocated) |
Lot Sizes & Investment Commitments
The primary lot size unit of this public listing is established at 600 shares. Retail and institutional application bands are structured as follows:
| Investor Class | Minimum Lots | Equity Shares | Total Outlay Amount |
|---|---|---|---|
| Retail (Min & Max Limit) | 2 Lots | 1,200 Shares | ₹2,49,600 |
| Small HNI (s-HNI Min) | 3 Lots | 1,800 Shares | ₹3,74,400 |
| Small HNI (s-HNI Max) | 8 Lots | 4,800 Shares | ₹9,98,400 |
| Big HNI (b-HNI Min) | 9 Lots | 5,400 Shares | ₹11,23,200 |
Balance Sheet & Financial Disclosures
The following financials showcase the balance sheet progression of Avience Biomedicals Limited over the last three reporting timelines:
| Financial Metric (₹ In Crores) | Period Ended Jan 31, 2026 (Restated) | Fiscal Year Ended Mar 31, 2025 (Restated) | Fiscal Year Ended Mar 31, 2024 (Restated) |
|---|---|---|---|
| Total Capital Assets | 66.07 | 56.52 | 34.65 |
| Aggregate Revenue | 41.94 | 45.97 | 24.37 |
| Profit After Tax (PAT) | 5.74 | 7.23 | 2.14 |
| EBITDA | 10.34 | 11.41 | 4.08 |
| Net Worth | 28.52 | 22.78 | 6.21 |
| Debt-to-Equity Ratio | 0.94 | 0.97 | 2.44 |
Key Performance Ratios & Valuations:
Bidding Response & Subscription Dynamics
The issue garnered strong institutional and retail demand over its 3-day bidding window, ending in an overall subscription of 385.32 times.
| Investor Segment | Subscription (x) | Shares Offered | Shares Bid For |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 196.77x | 2,73,600 | 5,38,37,400 |
| Non-Institutional Investors (NII) | 597.23x | 2,07,000 | 12,36,27,600 |
| ├ Big HNI (> ₹10L portion) | 670.18x | 1,38,000 | 9,24,84,600 |
| ├ Small HNI (< ₹10L portion) | 451.35x | 69,000 | 3,11,43,000 |
| Retail Individual Investors (RII) | 401.36x | 4,81,200 | 19,31,32,800 |
| Aggregate Consolidated Total | 385.32x | 9,61,800 | 37,05,97,800 |
SWOT Analysis: Avience Biomedicals Ltd.
S Core Strengths
- ISO-certified, highly focused medical manufacturing with an established Noida facility.
- Highly diverse business model spanning In-Vitro Diagnostics (IVD), molecular diagnostics, and critical medical infrastructure.
- A healthy financial track record showing multi-fold profit scaling over two fiscal years.
W Inherent Weaknesses
- Substantial pre-existing debt profile with a debt-to-equity leverage standing at 0.94.
- The SME framework limits post-IPO liquidity options for early investors.
- Heavy structural dependency on B2G procurement tenders.
O Market Opportunities
- Proposed setting up of a larger, dedicated manufacturing facility in Noida’s Medical Device Park.
- Expanding domestic distribution partnerships into untapped rural healthcare markets.
- Growing international B2B demand for cost-effective, high-accuracy rapid testing.
T Industry Threats
- Rapid biological & medical tech obsolescence requires constant R&D expenditure.
- Severe threat from massive medical conglomerates and generic global importers.
- Ever-shifting drug control, license norms, and compliance pathways.
Primary Objectives of the Fundraise
The total targeted net capital of ₹26.27 Crore derived from the fresh issue is budgeted for the following strategic requirements:
| Proposed Capital Allocation Objective | Estimated Fund Requirement (₹ In Cr.) |
|---|---|
| Infrastructure setting up at YEIDA Medical Device Park (Plot No. 70, Sector 28, Gautam Buddha Nagar, UP) | 14.05 |
| Working Capital Reserves and Operational Support | 8.25 |
| General Corporate Intent & Expansion Expenditures | 3.97 |
| Consolidated Net Utilization Budget | 26.27 |
Corporate Promoters & Ownership Evolution
The leadership and founding core of Avience Biomedicals Limited are driven by:
- Mr. Dharam Deo Choudhary
- Mr. Ram Nagina Choudhary
- Mr. Janardan Pal
- Ms. Deepa Choudhary
Promoter Equity Evolution:
Anchor Investor Profile
To anchor institutional trust prior to the general public opening, the firm mobilized key anchor allocations on June 17, 2026.
| Anchor Placement Parameters | Valuations / Key Timelines |
|---|---|
| Total Anchor Allocated Capital | ₹8.52 Crore |
| Shares Issued to Anchors | 4,09,800 Equity Shares |
| Anchor Lock-in Expiry (50% Volume - 30 Days) | July 23, 2026 |
| Anchor Lock-in Expiry (Remaining 50% - 90 Days) | September 21, 2026 |
Market Outlook & Analyst Consensus
Avience Biomedicals is showing strong performance in top and bottom-line scaling during its reporting period. The strategic move to construct a dedicated, advanced production facility at the YEIDA Medical Device Park is expected to significantly increase capacity and efficiency over the long term.
Valued at a post-IPO price-to-earnings (P/E) ratio of 16.56x, the pricing appears fair relative to peers in the diagnostic and medical technology sector. Given the company's compact post-issue base, long-term investors may expect a transition period before migrations to larger platforms can occur. Overall, analysts suggest a moderate investment strategy focused on long-term value.
Corporate Contacts & Issue Registrars
Avience Biomedicals Ltd.
Registered Address: C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi, 110058
Official Helpline: 1800-12-04-636
Corporate Mail: info@avienbio.com
Registrar of the Issue
Skyline Financial Services Pvt. Ltd.
Official Contact Number: 022-28511022
Allotment Enquiries Mail: ipo@skylinerta.com
Lead Manager Information
Fintellectual Corporate Advisors Private Limited
Serves as the Book Running Lead Manager (BRLM) to manage the book building process.
Final Overview & Market Perspective
Avience Biomedicals Limited is positioning itself to capture key opportunities in India's expanding In-Vitro Diagnostics (IVD) and clinical testing sectors. Driven by rising domestic medical needs and supported by the upcoming YEIDA Medical Device Park facility, the company has established solid fundamentals. A P/E ratio of 16.56x makes the valuation reasonable relative to sector peers, while the high subscription levels highlight strong market interest in this medical technology business.